This table is a portion of the CCC PEP Quick Guide. It is intended to be used in conjunction with the Quick Guide and not as a standalone document.

### Testing Recommendations for the Exposed Person (HCV)

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Baseline testing</th>
<th>Initial follow-up</th>
<th>Final follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PEPline 2017</strong></td>
<td>HCV+ SP&lt;sup&gt;1&lt;/sup&gt; or SP has potential HCV risk factors</td>
<td>HCV Ab&lt;sup&gt;2&lt;/sup&gt;</td>
<td>6 weeks&lt;sup&gt;3&lt;/sup&gt; HCV RNA</td>
</tr>
<tr>
<td></td>
<td>SP HCV status unknown or SP is known and has no known HCV risk factors</td>
<td></td>
<td>Optional: 6 week HCV RNA</td>
</tr>
<tr>
<td><strong>CDC 2016&lt;sup&gt;6&lt;/sup&gt;</strong></td>
<td>HCV Ab&lt;sup&gt;2&lt;/sup&gt;</td>
<td>≥3 weeks HCV RNA</td>
<td>Optional: ≥6 month HCV Ab&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>CDC 2001&lt;sup&gt;7&lt;/sup&gt;</strong></td>
<td>HCV Ab and ALT</td>
<td>If earlier diagnosis desired: HCV RNA at 4-6 weeks</td>
<td>4-6 months HCV Ab and ALT</td>
</tr>
</tbody>
</table>

Abbreviations: HCV+ = hepatitis C positive; SP = source person; Ab = antibody; ALT = alanine aminotransferase

1. For purposes of initial post-exposure management, a source person can be considered HCV+ if either HCV antibody or HCV RNA is positive (RNA is the more accurate indicator, as some people may have positive HCV antibody but are subsequently found to be HCV RNA negative).

2. If HCV antibody is positive at any point, follow-up HCV RNA testing is required. Persons with confirmed positive HCV RNA results should be referred for further evaluation and care.
The PEPline recommends initial HCV follow-up test at 6 weeks, to coincide with the first HIV follow-up test. There are no data that establish a clinical advantage to testing at 3 weeks vs. 6 weeks [Glynn, et al, Busch, et al, Hajarizadeh, et al]. HCV RNA becomes detectable beginning at 3 weeks. Testing earlier than 6 weeks can be performed at the discretion of the managing clinician, especially if preliminary assessment is needed. Positive HCV RNA indicates likely infection. However, approximately 25% of new infections will clear spontaneously [Naggie, et al]. Refer to an experienced provider for additional counseling, testing, and follow-up if positive.

There are no data that establish a clinical advantage to testing at 3 weeks vs. 6 weeks [Glynn, et al, Busch, et al, Hajarizadeh, et al]. HCV RNA becomes detectable beginning at 3 weeks. Testing earlier than 6 weeks can be performed at the discretion of the managing clinician, especially if preliminary assessment is needed. Positive HCV RNA indicates likely infection. However, approximately 25% of new infections will clear spontaneously [Naggie, et al]. Refer to an experienced provider for additional counseling, testing, and follow-up if positive.

In HCV infection, HCV RNA can be transiently undetectable [Mosley, et al]. Additionally, HCV antibodies develop slowly. Therefore, even though an early initial negative HCV RNA can be preliminarily reassuring, the PEPline recommends further HCV antibody testing at 6 months (24 weeks) post-exposure to confirm transmission did not occur.

An interval (i.e. 12-16 week) HCV antibody test may provide some reassurance for exposed persons in many instances (and align with HIV surveillance). However: (a) testing at this time point may not impact overall exposure management significantly, and (b) it is not sufficiently sensitive to completely exclude HCV transmission. Even at 15 weeks, only about 80% of HCV-infected persons will have positive HCV Ab [MMWR rr5005a1]. Therefore, the 6 month (24-week) HCV antibody test is considered to be conclusive in excluding HCV acquisition: ≥97% will be positive at 6 months post exposure [MMWR rr5005a1].


Note regarding exposed persons with symptoms: Symptoms of a viral illness compatible with acute HCV at any point up to 6 months post-exposure should prompt immediate evaluation.

Note regarding availability and feasibility of HCV RNA testing: HCV RNA testing might not be available or feasible at all institutions. If it is not possible to obtain the recommended HCV RNA testing, surveillance using antibody testing is essential in assessing HCV transmission.

Note regarding hepatic enzyme testing: The PEPline does not recommend routine liver enzyme testing for follow-up because of the possibility of abnormal results from causes other than HCV.

References cited:
Glynn SA, Wright DJ, Kleinman SH, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion. 2005 June; 45(6):994–1002.